Butantan Institute, a biomedical research centre in Brazil, has developed a potential COVID-19 vaccine and will seek regulatory approval to begin human trials, according to two sources familiar with the matter, Reuters news agency reported on Friday,
The sources said that Butantan plans to test the vaccine, named Butanvac, on 1,800 volunteers over two phases.
This vaccine has been 100% developed in Brazil by an international consortium that also includes Vietnam and Thailand.
Production on a large scale is anticipated to start in May 2021.
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits